Genomic Expression Inc. has developed proprietary RNA analysis platform - called OneRNA® -- for personalized medicine. Platform analyzes patient's tumor's RNA to identify approved drugs and clinical trials, particularly for breast and ovarian cancers, to create individualized treatment plans. Company focused on expanding its sales and marketing to bring its technology to more patients. OneRNA® Platform: is the core technology - comprehensive RNA analysis thelping to identify effective treatments for patients who don't respond to standard cancer therapies. Personalized Medicine: By linking RNA sequencing to approved therapies and clinical trials, the company aims to provide personalized treatment options. Disease Agnostic: The platform's technology is designed to be applicable to various diseases beyond its initial focus on breast and ovarian cancers
